When the patients with chronic renal failure need drug therapy,we must select the appropriate drugs and adjust the drug delivery methods and dosage according to the renal function of these patients,at the same time we have to consider the factors such as age,sex,weight,combined medication,damage of other organs and so on,the therapeutic drug concentration monitoring should be paid attention to.For patients with blood purification,if the drug mainly removed by the kidneys,adjustments of drug administration must be based on the molecular weight of drug,volume of distribution,protein binding rate,mode of dialysis and hemodialyzer.We must ensure the drug efficacy and reduce the adverse reactions of drugs at the same time in the patients of renal insufficiency.

Enterovirus A, Human ; Enterovirus Infections ; pathology ; Female ; Hemorrhage ; etiology ; virology ; Humans ; Infant ; Male ; Pulmonary Edema ; etiology ; virology

Systemic Inflammatory Response Syndrome ; virology ; Virus Diseases

Asian Continental Ancestry Group ; China ; Humans ; Sepsis ; Terminology as Topic ; Translations

Anti-Bacterial Agents ; therapeutic use ; Child ; Humans ; Practice Guidelines as Topic ; Sepsis ; classification ; complications ; diagnosis ; drug therapy ; physiopathology

Mechanism studies in the gene regulation in the eukaryotic cells is one of the momentous areas in molecular biology.Regulation at transcription level is a complex progress with multiple steps with the presence of the gene functions.There exist ubiquitous occurrence of transcription factors in mammalian tissues and biodiversity in the factors.These transcription factors are found to relate closely to various carcinogeneses,including cell proliferation,apoptosis,invasion and angiogenesis.Understanding of transcription factors and their action mechanisms,through the activation and inhibition of transcription factors,would potentially lead to the discovery of new entities in the targeting treatment and prevention of the cancer diseases.

Neonatal hypoxic-ischemic brain damage (HIBD) is a complex disease process in which injury severity,duration and timing of the antenatal injury are difficult to discern.HIBD triggers a cascade of pathophysiological events (blood-brain barrier damage,oxidative stress,inflammation,glutamate excitotoxicity,energy depletion and cell death) leading to brain damage and neonatal death.Under this background,the changing of biomarkers in different types of biological fluids able to be detected and prognosed HIBD.

Objective To explore the clinical curative effect of ursodeoxycholic acid combined with reduced glutathione for non-alcoholic fatty liver disease.Methods 128 patients with non-alcoholic fatty liver disease in our hospital were selected, and they were randomly divided into control group and research group,64 cases in each group.The control group received ursodeoxycholic acid capsules, the research group received reduced glutathione tablet on the basis of ursodeoxycholic acid capsules,the two groups received treatment of two periods, each period had one and half months.The liver function and blood lipid were detected and compared between the two groups.Results The total clinical effective rate of the research group was 93.75%, which of the control group was 68.75% (x2=20.5,P=0.000),the difference was statistically significant.After treatment, liver function (ALT, AST, TBIL, GGT and ALP) and lipid levels (TG and CHO) of the two groups were improved significantly[the control group:before treatment (138.75±30.63) IU/L,(161.72±55.61) IU/L,(183.65±58.47) μmol/L,(213.65±40.35) IU/L,(82.38±23.15) IU/L,(2.85±0.77) μmol/L,(6.45±0.37) μmol/L, after treatment (66.38±26.31) IU/L,(65.39±22.15) IU/L,(92.38±36.15) μmol/L,(99.68±36.72) IU/L,(30.23±10.36) IU/L,(1.92±0.58) mol/L,(5.39±0.53) μmol/L;the research group before treatment (141.25±32.53) IU/L,(157.56±58.31) IU/L,(190.23±51.27) μmol/L,(223.72±43.18) IU/L,(80.86±21.85) IU/L,(2.92±0.73) μmol/L,(6.43±0.82) μmol/L, after treatment (37.64±11.25) IU/L,(36.25±11.83) IU/L,(47.67±8.32) μmol/L,(70.52±26.31) IU/L,(16.69±7.32) IU/L,(1.32±0.63) μmol/L,(4.31±0.63) μmol/L],the differences were statistically significant(the control group :t=14.3,12.9,10.6,16.7,16.4,7.7,13.1,all P<0.01;the research group:t=24.1,25.4,21.9,24.2,16.1,13.3,16.4,all P<0.01),but these indicators of the research group were improved significantly better than those of the control group, the differences were statistically significant(t=8.0,9.3,9.6,8.5,8.5,5.6,10.5;all P<0.01).Conclusion The clinical curative effect of research group is distinct, safe and has no obvious adverse reactions, which is worthy of clinical application.

Clinical research initiated by researchers is one of the important means to promote new understanding of drugs and treatment methods.At this stage,the clinical researches initiated by the researchers frequently appear all kinds of irregularities.In order to solve out this problem,the paper points out suggestions about strengtheningself-discipline of researchers,self-regulation of conscience,and self-responsibility of carefulness.Meanwhile,it is also important to abide by the relevant ethical codes and consciously accept the third party supervision of IRB.Joint efforts should be made to protect safety and rights of human subjects.

Objective To observe the efficacy of irbesartan combined with metoprolol in the treatment of chronic congestive heart failure.Methods From April 2015 to April 2016,60 patients with chronic congestive heart failure in Central Hospital of Zhuji were randomly divided into the observation group and the control group,30 cases in each group.The two groups were given conventional treatment,the control group was treated with metoprolol,and the observation group was treated with irbesartan combined with metoprolol.The changes of left ventricular ejection fraction (LVEF),left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD),heart rate,systolic pressure and diastolic pressure before and after treatment in two groups were observed.And the clinical efficacy of the two groups was compared.Results After treatment,compared with the control group,the heart function index of the observation group changed obviously,LVEF increased (t=5.88,P＜0.01),LVESD and LVEDD significantly decreased (t=7.19,4.11,all P＜0.01).The heart rate of the observation group was significantly slowed down (t=2.72,P＜0.01),systolic blood pressure and diastolic blood pressure were also significantly reduced (t=2.93,3.98,all P＜0.01).The total effective rate of the observation group was 93.3％,which of the control group was 73.3％,the difference was statistically significant (χ2=4.32,P＜0.05).ConclusionIrbesartan combined with metoprolol in the treatment of chronic congestive heart failure has significant clinical efficacy,is conducive to ease the clinical symptoms and improve heart function effectively.